Cidara Therapeutics and WuXi XDC Expand Collaboration for IND-enabling CMC Development to Advance Cidara's CD73 Oncology DFC Program Seite 1
01.02.2023 - Agreement builds upon the existing relationship with WuXi XDC for CMC development and GMP manufacturing of Cidara’s CD388 drug-Fc conjugate (DFC) for influenza to now include the oncology programSAN DIEGO and SHANGHAI, China, Feb. 01, 2023 (GLOBE ... Seite 1
Source: wallstreet-online.de